Preliminary observation on the clinical tolerance of interferon-beta in cancer patients

Tumori. 1985 Feb 28;71(1):45-9. doi: 10.1177/030089168507100108.

Abstract

Nine patients with metastatic solid tumors were given IFN-beta by i.v. bolus injections. Six escalating doses (from 1 to 9 X 10(6) IU) followed by 6 additional injections at the dose of 9 X 10(6) IU were administered every other day (schedule A) in 3 of the 9 patients. IFN dose was also increased to a maximum of 46 X 10(6) IU, and 12 individual injections of 1, 2, 3.3, 5, 7, 9, 12, 16, 21, 27, 34 and 46 X 10(6) IU of IFN were given over a minimum of a 24-day period (schedule B) in 6 of the 9 patients. The single maximal tolerated dose ranged from 9 to 46 X 10(6) IU. The toxicity of IFN-beta given as scheduled in this study was significant but acceptable.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Humans
  • Injections, Intravenous
  • Interferon Type I / adverse effects
  • Interferon Type I / therapeutic use*
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasms / blood
  • Neoplasms / therapy*
  • Time Factors

Substances

  • Interferon Type I